MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Endocyte Company Profile (NASDAQ:ECYT)

Consensus Ratings for Endocyte (NASDAQ:ECYT) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.50 (279.94% upside)

Analysts' Ratings History for Endocyte (NASDAQ:ECYT)
Show:
DateFirmActionRatingPrice TargetActions
5/4/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016WedbushReiterated RatingOutperform$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/20/2016Credit SuisseInitiated CoverageOutperform$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015RBC CapitalLower Price TargetOutperform$13.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2015Cantor FitzgeraldReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2014Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2014Citigroup Inc.Reiterated RatingNeutral$8.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/25/2014Chardan CapitalReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Endocyte (NASDAQ:ECYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/4/2016Q116($0.25)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.30)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.24)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.25)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214$0.10$0.52$26.62 million$49.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2014Q114($0.14)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Endocyte (NASDAQ:ECYT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.29)($0.27)($0.28)
Q2 20162($0.29)($0.27)($0.28)
Q3 20162($0.30)($0.29)($0.30)
Q4 20161($0.29)($0.29)($0.29)
Q1 20171($0.32)($0.32)($0.32)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)
Dividend History for Endocyte (NASDAQ:ECYT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Endocyte (NASDAQ:ECYT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/9/2014Allen RitterVPSell1,000$21.16$21,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Allen RitterVPSell8,000$33.11$264,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Allen RitterVPSell2,000$17.06$34,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Allen RitterVPSell6,000$14.36$86,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Endocyte (NASDAQ:ECYT)
DateHeadline
06/23/16 06:44 AMEndocyte, Inc. (NASDAQ:ECYT) Updated Price Targets - FTSE News
06/22/16 08:56 PMStrong Buy Calls Count For Endocyte, Inc. (NASDAQ:ECYT) At 2 - Investor Newswire
06/22/16 03:52 PMEndocyte, Inc. (NASDAQ:ECYT) Stock Momentum Hits Weakness - CML News
06/22/16 08:26 AMStock in the Spotlight: Endocyte, Inc. (NASDAQ:ECYT) - iStreetWire
06/21/16 03:33 PMShining on Major News: Endocyte, Inc. (NASDAQ:ECYT), Celgene Corporation (NASDAQ:CELG), ePlus inc. (NASDAQ ... - KC Register
06/20/16 03:40 PMEndocyte Announces A Change at The Top
06/20/16 03:40 PMEndocyte (ECYT) Names Mike Sherman as President, CEO
06/20/16 09:59 AMStock Update (NASDAQ:ECYT): Endocyte, Inc. Appoints Mike Sherman as President and Chief Executive Officer - Smarter Analyst
06/20/16 08:09 AMEndocyte Appoints Mike Sherman as President and Chief Executive Officer - [at noodls] - WEST LAFAYETTE, Ind., June 20, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized ...
06/20/16 07:53 AMENDOCYTE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
06/20/16 07:46 AM8:46 am Endocyte CFO/COO Mike Sherman appointed as CEO, succeeding Ron Ellis, who resigned effective immediately -
06/19/16 03:32 PMThis Weeks Broker Views For Endocyte, Inc. (NASDAQ:ECYT) - Fiscal Standard
06/16/16 08:58 PMTrend Of Rating Given To Endocyte, Inc. (NASDAQ:ECYT) - Investor Newswire
06/08/16 08:31 AMEndocyte Inc. (ECYT) is Trading Lower on Unusual Volume for June 06 - Equities.com
06/05/16 08:35 AMEndocyte, Inc. (ECYT) Given Outperform Rating at Wedbush - Let Me Know About This
06/04/16 09:05 PMEndocyte, Inc. (ECYT) Given “Buy” Rating at Cowen and Company - Let Me Know About This
06/03/16 03:56 PMBuy, Sell Or Hold Rating For Endocyte, Inc. (NASDAQ:ECYT)? - Share Trading News
06/01/16 10:02 PMEndocyte, Inc. (NASDAQ:ECYT) Stock Update & Estimates - Stock Tick Tock - Endocyte, Inc. (NASDAQ:ECYT) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Endocyte, Inc. (NASDAQ:ECYT) to post earnings of $-0.27 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/01/16 10:02 PMInsiders Are Gradually Buying Endocyte, Inc. (NASDAQ:ECYT) - HNN - Insiders Are Gradually Buying Endocyte, Inc. (NASDAQ:ECYT)HNNAccording to the latest SEC filings, insiders at Endocyte, Inc. (NASDAQ:ECYT) have increased their position in the stock by 4.00% over the past 6 months. Insiders now own 2.60% of total outstanding shares. There are both legal and illegal types of ...and more »
05/30/16 08:22 AMStock Rating Review for Endocyte, Inc. (NASDAQ:ECYT) - HNN - Stock Rating Review for Endocyte, Inc. (NASDAQ:ECYT)HNNCovering equity analysts presently have a consensus stock rating of 1.67 on shares of Endocyte, Inc. (NASDAQ:ECYT). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is ...and more »
05/26/16 05:12 PMEndocyte (ECYT) Will Present Updated EC1456, EC1169 Data at ASCO 2016 - StreetInsider.com - Endocyte (ECYT) Will Present Updated EC1456, EC1169 Data at ASCO 2016StreetInsider.comEndocyte, Inc. (Nasdaq: ECYT) announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2016, in Chicago. Updated ...and more »
05/26/16 03:27 PMEndocyte to Announce Updated Data on EC1456 and EC1169 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting - [at noodls] - WEST LAFAYETTE, Ind., May 26, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized ...
05/26/16 08:24 AMInsiders Are Gradually Buying Endocyte, Inc. (NASDAQ:ECYT) - Wall Street Hints and News - Insiders Are Gradually Buying Endocyte, Inc. (NASDAQ:ECYT)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Endocyte, Inc. (NASDAQ:ECYT) have increased their position in the stock by 4.02% over the past 6 months. Insiders now own 2.60% of total outstanding shares. There are both legal and illegal types of ...and more »
05/25/16 05:06 PMEarnings Review and Stock Rundown for Endocyte, Inc. (NASDAQ:ECYT) - Wall Street Hints and News - Earnings Review and Stock Rundown for Endocyte, Inc. (NASDAQ:ECYT)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Endocyte, Inc. (NASDAQ:ECYT) to post ...
05/23/16 05:09 PMEye Catching Stocks: Verizon Communications Inc. (NYSE:VZ), Endocyte, Inc. (NASDAQ:ECYT), Ennis Inc. (NYSE:EBF ... - KC Register - Eye Catching Stocks: Verizon Communications Inc. (NYSE:VZ), Endocyte, Inc. (NASDAQ:ECYT), Ennis Inc. (NYSE:EBF ...KC RegisterEndocyte, Inc. (NASDAQ:ECYT) traded 113384 shares and its share price increased 2.31% to close at $3.55. Company has 2.60% insider ownership. Endocyte, Inc. (NASDAQ:ECYT) quarterly performance is 10.94% while its year to date (YTD) performance ...
05/23/16 04:04 PMETF’s with exposure to Endocyte, Inc. : May 23, 2016 -
05/22/16 09:39 PMStock Rating Review for Endocyte, Inc. (NASDAQ:ECYT) - Wall Street Hints and News - Stock Rating Review for Endocyte, Inc. (NASDAQ:ECYT)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1.67 on shares of Endocyte, Inc. (NASDAQ:ECYT). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is ...and more »
05/18/16 09:15 AMShare Performance and Target Price Review for Endocyte, Inc. (NASDAQ:ECYT) - Wall Street Hints and News - Share Performance and Target Price Review for Endocyte, Inc. (NASDAQ:ECYT)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Endocyte, Inc. (NASDAQ:ECYT ...and more »
05/18/16 09:15 AMShare Recap and Earnings Focus on Endocyte, Inc. (NASDAQ:ECYT) - Wall Street Hints and News - Share Recap and Earnings Focus on Endocyte, Inc. (NASDAQ:ECYT)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Endocyte, Inc.and more »
05/17/16 10:06 PMRevenue Update on Endocyte(NASDAQ:ECYT) - Trade Calls - Revenue Update on Endocyte(NASDAQ:ECYT)Trade CallsEndocyte Inc. (Endocyte) is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases. The Company's pipeline includes: Vintafolide (Vynfinit or EC145) which delivers potent vinca alkaloid chemotherapy ...and more »
05/16/16 04:52 PMConsensus Rating Review for Endocyte, Inc. (NASDAQ:ECYT) - Wall Street Hints and News - Consensus Rating Review for Endocyte, Inc. (NASDAQ:ECYT)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1.67 on shares of Endocyte, Inc. (NASDAQ:ECYT). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or ...and more »
05/15/16 05:33 PMEndocyte Incorporated (NASDAQ:ECYT) Sellers Covered 1.01% of Their Shorts - Wall Street Hints and News - Endocyte Incorporated (NASDAQ:ECYT) Sellers Covered 1.01% of Their ShortsWall Street Hints and NewsThe short interest to Endocyte Incorporated's float is 10.29%. The stock increased 3.64% or $0.12 on May 13, hitting $3.42. About 151,858 shares traded hands. Endocyte, Inc. (NASDAQ:ECYT) has declined 26.92% since October 8, 2015 and is downtrending.and more »
05/13/16 05:26 PMStocks inside Investors Spotlight: NovoCure Limited (NASDAQ:NVCR) , Endocyte, Inc. (NASDAQ:ECYT) - Street Updates - Stocks inside Investors Spotlight: NovoCure Limited (NASDAQ:NVCR) , Endocyte, Inc. (NASDAQ:ECYT)Street UpdatesIn the past trading session, Endocyte, Inc. (NASDAQ:ECYT) highlighted downward shift of -2.08% or -0.07 points to $3.30. The company traded a volume of 175.64 thousand shares under average volume of 192.88 thousand shares. Trailing twelve month ...
05/12/16 01:58 PMETF’s with exposure to Endocyte, Inc. : May 12, 2016 -
05/11/16 10:35 AMEndocyte, Inc. :ECYT-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 03:38 AMEndocyte Inc. (ECYT) Jumps 5.15% on May 09 - Equities.com - Endocyte Inc. (ECYT) Jumps 5.15% on May 09Equities.comEndocyte Inc. (ECYT) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 5.15% to $3.47, representing a gain of $0.17 per share. Some 269,479 shares traded hands on 1,096 trades, compared with an average daily ...and more »
05/09/16 05:20 PMCheck on Analyst Ratings Endocyte, Inc. (NASDAQ:ECYT) - B.O.D.Y Confidential - Check on Analyst Ratings Endocyte, Inc. (NASDAQ:ECYT)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1.67 on shares of Endocyte, Inc. (NASDAQ:ECYT). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 scale. A 1 or ...and more »
05/09/16 04:25 PMENDOCYTE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/08/16 05:33 PMNext Weeks Broker Price Targets For Endocyte, Inc. (NASDAQ:ECYT) - Share Trading News - Next Weeks Broker Price Targets For Endocyte, Inc. (NASDAQ:ECYT)Share Trading NewsEndocyte, Inc. has a 50 day moving average of 3.60 and a 200 day moving average of 3.84. The stock's market capitalization is 138.52M, it has a 52-week low of 2.65 and a 52-week high of 6.35. The share price of the company (NASDAQ:ECYT) was down ...
05/06/16 11:03 AMENDOCYTE INC Files SEC form 10-Q, Quarterly Report -
05/05/16 03:01 PMEndocyte (ECYT) Reports Narrower than Expected Q1 Loss -
05/05/16 05:52 AMEdited Transcript of ECYT earnings conference call or presentation 4-May-16 12:30pm GMT -
05/04/16 10:32 PMEarnings Outlook on Endocyte, Inc. (NASDAQ:ECYT) - B.O.D.Y Confidential - Earnings Outlook on Endocyte, Inc. (NASDAQ:ECYT)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Endocyte, Inc. (NASDAQ:ECYT)'s next earnings release which is expected to be posted on or around 2016-05-04. Sell-side research firms on Wall Street are expecting that the company will post EPS of $-0.26 for ...and more »
05/04/16 10:32 PMCompany Update (NASDAQ:ECYT): Endocyte, Inc. Reports First Quarter 2016 Financial Results - Smarter Analyst - Company Update (NASDAQ:ECYT): Endocyte, Inc. Reports First Quarter 2016 Financial ResultsSmarter AnalystEndocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the first quarter ending March 31, 2016, and provided a ...
05/04/16 07:53 AMEndocyte (ECYT) Reports a Narrower Q1 Loss -
05/04/16 07:30 AMEndocyte Inc Earnings Call scheduled for 8:30 am ET today -
05/04/16 07:22 AMEndocyte reports 1Q loss -
05/04/16 07:10 AMEndocyte Reports First Quarter 2016 Financial Results - [at noodls] - - Data fromPhase 1 Dose Escalation Studies of EC1456 and EC1169 to be Presented at ASCO - - Expansion Phase of Trials in Targeted Patients Expected to Yield Efficacy Data in 2016 - - Promising Preclinical ...
05/04/16 06:07 AMQ1 2016 Endocyte Inc Earnings Release - Time Not Supplied -
05/02/16 05:45 PMWatch List: Endocyte (NASDAQ:ECYT), Cousins Properties (NYSE:CUZ), The Walt Disney Company (NYSE:DIS ... - KC Register - Watch List: Endocyte (NASDAQ:ECYT), Cousins Properties (NYSE:CUZ), The Walt Disney Company (NYSE:DIS ...KC RegisterEndocyte, Inc. (NASDAQ:ECYT) announced that the company will host a conference call on Wednesday, May 4th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update. Endocyte, Inc. (NASDAQ:ECYT) belongs to ...and more »
About Endocyte

Endocyte logoEndocyte Inc. (Endocyte) is a biopharmaceutical company, developing therapies for the treatment of cancer and inflammatory diseases. The Company's pipeline includes: Vintafolide (Vynfinit or EC145), which delivers potent vinca alkaloid chemotherapy directly to cancer cells by targeting the folate receptor expressed on cancer cells, but not on most normal cells; Folate-Tubulysin (EC1456), an SMDC (small molecule drug conjugates) consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH); EC0652, a prostate-specific membrane antigen (PSMA)-targeted molecular imaging agent; EC1169, an investigational, injectable, PSMA-targeted SMDC; Etarfolatide (Folcepri or EC20), a folate-targeted molecular imaging agent; EC1669, a new approach to inflammation therapy, targeting an anti-folate drug to activated macrophages expressing folate receptors; EC0371, a folate-targeted, water-soluble form of rapamycin, and EC1788, a Folate-targeted SMDC.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: ECYT
  • CUSIP: 29269A10
Key Metrics:
  • Previous Close: $3.52
  • 50 Day Moving Average: $3.66
  • 200 Day Moving Average: $3.55
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $138.68M
  • Current Quarter EPS Consensus Estimate: $-1.10 EPS
Additional Links:
Endocyte (NASDAQ:ECYT) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha